GH Research PLC

NASDAQ:GHRS

Biotechnology

Healthcare
$18.25 -0.18%

-$0.04 today

Market cap
$1.25B
Beta
1.31
P/E (TTM)
-23.8
EPS (TTM)
-$0.91
52W Low $11.32High $25.94

Volume 0.46M

Average 0.23M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$43.55M

FY 2025 · Annual

Investing Cash Flow

$46.17M

FY 2025 · Annual

-29.1% YoY

Financing Cash Flow

$139.65M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.2M)(22.46M)(35.59M)(38.96M)(48.26M)
Depreciation & Amortization19K47K315K315K335K
Deferred Income Tax(5.92M)0000
Stock-Based Compensation366K1.67M2.29M1.17M0
Change in Working Capital(559K)2.16M1.65M188K(3.09M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital(559K)2.16M1.65M188K(3.09M)
Other Non-Cash Items9K(7.62M)(2M)(5M)7.46M
Operating Cash Flow(15.28M)(26.2M)(33.34M)(42.29M)(43.55M)
Capital Expenditures(104K)(67K)(100K)(49K)(121K)
Acquisitions (Net)00000
Purchases of Investments0(84.62M)(54M)00
Sales of Investments00065.18M46.29M
Other Investing Activities00000
Investing Cash Flow(104K)(84.69M)(54.1M)65.14M46.17M
Debt Repayment00(219K)(304K)0
Common Stock Issued309.2M015K0139.85M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(22.75M)000(197K)
Financing Cash Flow286.45M0(204K)(304K)139.65M
Effect of Forex Changes(179K)66K105K(175K)3.19M
Net Change in Cash270.88M(110.82M)(87.54M)22.37M145.46M
Free Cash Flow(15.39M)(26.27M)(33.44M)(42.33M)(43.67M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$48.3M
+ D&A$335.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$3.1M
+ Other Non-Cash$7.5M
= Operating Cash Flow-$43.6M
- Capex-$121.0K
= Free Cash Flow-$43.7M

Analysis

FY2025 free cash flow is -$43.7M. FCF conversion is 90.5% of net income. Operating cash flow was -$43.6M, with capex of -$121.0K. The largest bridge item is Other Non-Cash at $7.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 13, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
6-K6-K filingOct 9, 2026
6-K6-K filingSep 11, 2026
4Statement of changes in beneficial ownershipSep 9, 2026

Does GHRS generate free cash flow?

GH Research PLC (GHRS) generated -$43.67M of free cash flow in fiscal 2025.

How much operating cash flow does GHRS produce?

Operating cash flow was -$43.55M, before capital expenditures of $121,000.00.